Commitments and Contingencies	12 Months Ended
Dec. 31, 2025
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	13. Commitments and Contingencies The Company has contracted with various consultants and third parties to assist in pre-clinical research and development and clinical trials work for the Company’s leading drug compounds. The contracts are terminable at any time but obligate the Company to reimburse the providers for any time or costs incurred through the date of termination. Funding Commitments In September 2023, the Company entered into a work order with a third-party contract research organization (“CRO”) to provide services with respect to the Company’s Phase 2 trial of LB-102 for schizophrenia. As of December 31, 2025, the Company has paid all outstanding amounts related to the Phase 2 clinical trial and there are no remaining amounts to be invoiced. In November 2025, the Company entered into a work order with a third-party to provide clinical trial services with respect to the Company's Phase 3 trial and Open Label. As of December 31, 2025, the Company is committed to fund approximately $0.5 million in advances to the service provider and expects to pay prior to March 31, 2026. In December 2025, the Company entered into a work order with a third-party CRO to provide services with respect to the Company's Phase 3 clinical trial of LB-102 for schizophrenia (“Phase 3 trial”). As of December 31, 2025, the Company is committed to fund approximately $15.8 million in advances to the CRO and expects to pay prior to March 31, 2026. In December 2025, the Company entered into a start up work order with a third-party CRO to provide services with respect to the Company's Open Label Safety and Tolerability Study of LB-102 for schizophrenia (“Open Label”). As of December 31, 2025, the Company is committed to fund approximately $11.4 million in advances to the CRO and expects to pay prior to March 31, 2026. As of December 31, 2025, the Company is committed to fund approximately $1.0 million for various research and manufacturing projects and expects to pay prior to March 31, 2026. The Company enters into contracts in the normal course of business with contract development and manufacturing organizations (“CDMOs”) and other third parties for preclinical research studies and testing and manufacturing services, which are generally cancelable upon prior written notice. Payments due upon cancellation may consist of payments for services provided or expenses incurred, including noncancelable obligations of the Company’s service providers, up to the date of cancellation, and may also include termination penalties. As of December 31, 2025 and 2024, the Company had no outstanding liabilities related to such items. Contingencies In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business. The Company records accruals for such loss contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. The Company, in accordance with this guidance, does not recognize gain contingencies until realized. The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities as of December 31, 2025.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2025

Commitments and Contingencies Disclosure [Abstract]

13. Commitments and Contingencies

The Company has contracted with various consultants and third parties to assist in pre-clinical research and development and clinical trials work for the Company’s leading drug compounds. The contracts are terminable at any time but obligate the Company to reimburse the providers for any time or costs incurred through the date of termination.

Funding Commitments

In September 2023, the Company entered into a work order with a third-party contract research organization (“CRO”) to provide services with respect to the Company’s Phase 2 trial of LB-102 for schizophrenia. As of December 31, 2025, the Company has paid all outstanding amounts related to the Phase 2 clinical trial and there are no remaining amounts to be invoiced.

In November 2025, the Company entered into a work order with a third-party to provide clinical trial services with respect to the Company's Phase 3 trial and Open Label. As of December 31, 2025, the Company is committed to fund approximately $0.5 million in advances to the service provider and expects to pay prior to March 31, 2026.

In December 2025, the Company entered into a work order with a third-party CRO to provide services with respect to the Company's Phase 3 clinical trial of LB-102 for schizophrenia (“Phase 3 trial”). As of December 31, 2025, the Company is committed to fund approximately $15.8 million in advances to the CRO and expects to pay prior to March 31, 2026.

In December 2025, the Company entered into a start up work order with a third-party CRO to provide services with respect to the Company's Open Label Safety and Tolerability Study of LB-102 for schizophrenia (“Open Label”). As of December 31, 2025, the Company is committed to fund approximately $11.4 million in advances to the CRO and expects to pay prior to March 31, 2026.

As of December 31, 2025, the Company is committed to fund approximately $1.0 million for various research and manufacturing projects and expects to pay prior to March 31, 2026.

The Company enters into contracts in the normal course of business with contract development and manufacturing organizations (“CDMOs”) and other third parties for preclinical research studies and testing and manufacturing services, which are generally cancelable upon prior written notice. Payments due upon cancellation may consist of payments for services provided or expenses incurred, including noncancelable obligations of the Company’s service providers, up to the date of cancellation, and may also include termination penalties. As of December 31, 2025 and 2024, the Company had no outstanding liabilities related to such items.

Contingencies

In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business. The Company records accruals for such loss contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. The Company, in accordance with this guidance, does not recognize gain contingencies until realized. The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities as of December 31, 2025.